横浜市立大学大学院 医学研究科 幹細胞免疫制御内科学血液・リウマチ・感染症内科

MENU

業績

2018年

血液グループ

原著論文: 症例報告を含む

  1. Arima N, Kanda J, Tanaka J, Yabe T, Morishima Y, Kim SW, Najima Y, Ozawa Y, Eto T, Kanamori H, Mori T, Kobayashi N, Kondo T, Nakamae H, Uchida N, Inoue M, Fukuda T, Ichinohe T, Atsuta Y, Kanda Y: Homozygous HLA-C1 is associated with reduced risk of relapse after HLA-matched transplantation in patients with myeloid leukemia. Biol Blood Marrow Transplant 24(4): 717-725, 2018.
  2. Fujimaki K, Hattori Y, Nakajima H: 10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation. Int J Hematol 107: 709-711,2018.
  3. Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T: Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol. 97(11): 2081-2088, 2018.
  4. Fujiwara S, Fujishima N, Kanamori H, Ito M, Sugimoto T, Saito S, Sakaguchi T, Nagai K, Masuoka H, Nagai K, Morita A, Kino S, Tanaka A, Hasegawa Y, Yokohama A, Fujino K, Makino S, Matsumoto M, Takeshita A, Muroi K: Released washed platelet concentrates are effective and safe in patients with a history of transfusion reactions. Transfus Apher Sci 57(6): 746-751, 2018.
  5. Goto T, Tanaka T, Sawa M, Ueda Y, Ago H, Chiba S, Kanamori H, Nishikawa A, Nougawa M, Ohashi K, Okumura H, Tanimoto M, Fukuda T, Kawashima N, Kato T, Okada K, Nagafuji K, Okamoto SI, Atsuta Y, Hino M, Tanaka J, Miyamura K: Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. Int J Hematol 107(2): 211-221, 2018.
  6. Harada K, Doki N, Aoki J, Mori J, Machida S, Masuko M, Uchida N, Najima Y, Fukuda T, Kanamori H, Ogawa H, Ota S, Ogawa K, Takahashi S, Kasai M, Maeda A, Nagafuji K, Kawakita T, Ichinohe T, Atsuta Y: Outcomes after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia harboring t(7;11)(p15;p15). Haematologica, 103: e69-e72, 2018.
  7. Harada K, Doki N, Hagino T, Miyawaki S, Ohtake S, Kiyoi H, Miyazaki Y, Fujita H, Usui N, Okumura H, Miyamura K, Nakaseko C, Fujieda A, Nagai T, Yamane T, Sakamaki H, Ohnishi K, Naoe T, Ohno R, Ohashi K: Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. Ann Hematol. 97(1): 73-81, 2018.
  8. Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Onizuka M, Takeshita A, Ishida F, Suzushima H, Ishizawa K, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group JALSG: Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leuk Res 66(3): 20-27, 2018.
  9. Hatta Y, Mizuta S, Matuso K, Ohtake S, Iwanaga M, Sugiura I, Doki N, Kanamori H, Ueda Y, Yoshida C, Dobashi N, Maeda T, Yujiri T, Monma F, Ito Y, Hayakawa F, Takeuchi J, Kiyoi H, Miyazaki Y, Naoe T. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. Ann Hematol 97(9): 1532-1545, 2018.
  10. Iriyama N, Sugimoto KJ, Sato E, Takaku T, Tokuhira M, Nakazato T, Ishikawa M, Fujita H, Fujioka I, Kimura Y, Asou N, Kizaki M, Komatsu N, Hatta Y, Kawaguchi T: Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis. Med Oncol. 35(11): 142, 2018.
  11. Ishii Y, Fujisawa S, Ando T, Suzuki T, Ishiyama Y, Kishimoto K, Hattori Y, Nakajima Y, Miyazaki T, Takasaki H, Matsumoto K, Koharazawa H, Taguchi J, Fujimaki K, Sakai R, Nakajima H: Primary uterine lymphoma: The Yokohama Cooperative Study Group for Hematology (YACHT) study. Asia Pac J Clin Oncol, 14(5): e455-e459, 2018.
  12. Ishii Y, Fujisawa S, Nigauri C, Ando T, Suzuki T, Ogusa E, Miyashita K, Motohashi K, Nakajima H: Peripheral Blood Monocyte Count is a Predictor of Successful Peripheral Blood Stem Cell Harvest After Chemo-Mobilization in Patients with Malignant Lymphoma. Indian J Hematol Blood Transfus, 34(2): 347-349, 2018.
  13. Itonaga H, Aoki K, Aoki J, Ishikawa T, Ishiyama K, Uchida N, Sakura T, Ohashi K, Kurokawa M, Ozawa Y, Matsuoka KI, Nakamura Y, Kimura F, Iwato K, Nawa Y, Hirokawa M, Kato K, Ichinohe T, Atsuta Y, Miyazaki Y: Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia: a Nationwide Retrospective Analysis in Japan. Biol Blood Marrow Transplant, 24: 840-848, 2018.
  14. Iwasaki H, Yamazaki H, Takasaki H, Suganuma N, Nakayama H, Toda S, Masudo K.: Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study. Oncol Lett, 16(6): 7271-7277, 2018.
  15. Kawamoto K, Miyoshi H, Suzuki T, Kozai Y, Kato K, Miyahara M, Yujiri T, Choi I, Fujimaki K, Muta T, Kume M, Moriguchi S, Tamura S, Kato T, Tagawa H, Makiyama J, Kanisawa Y, Sasaki Y, Kurita D, Yamada K, Shimono J, Sone H, Takizawa J, Seto M, Kimura H, Ohshima K. A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features. Haematologica, 103: 1018-1028, 2018.
  16. Kawamura K, Nakasone H, Kurosawa S, Yoshimura K, Misaki Y, Gomyo A, Hayakawa J, Tamaki M, Akahoshi Y, Kusuda M, Kameda K, Wada H, Ishihara Y, Sato M, Terasako-Saito K, Kikuchi M, Kimura SI, Tanihara A, Kako S, Kanamori H, Mori T, Takahashi S, Taniguchi S, Atsuta Y, Kanda Y: Refractory graft-versus-host disease-free, relapse-free survival as an accurate and easy-to-calculate endpoint to assess the long-term transplant success. Biol Blood Marrow Transplant, 24(7): 1521-1526, 2018.
  17. Konuma T, Mizuno S, Kondo T, Yamaguchi H, Fukuda T, Uchida N, Najima Y, Kanamori H, Ota S, Nakamae H, Nakamae M, Mizuno I, Sugita J, Onishi Y, Yokota A, Takahashi S, Kanda Y, Ichinohe T, Atsuta Y, Yano S: Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Ann Hematol, 97(11): 2173-2183, 2018.
  18. Kunimoto H, Meydan C, Nazir A, Whitfield J, Shank K, Rapaport F, Maher R, Pronier E, Meyer SC, Garrett-Bakelman FE, Tallman M, Melnick A, Levine RL, Shih AH: Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity. Cancer Cell, 33:44-59, 2018.
  19. Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T, Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S, Adachi S, Kiyoi H: Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. Int J Hematol, 107(2):201-210, 2018.
  20. Matsumoto K, Fujisawa S, Ando T, Koyama M, Koyama S, Ishii Y, Numata A, Yamamoto W, Motohashi K, Hagihara M, Nakajima H: Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study. Turk J Haematol, 35(3): 181-184, 2018.
  21. Miyaoka M, Kikuti Y, Carreras J, Ikoma H, Hiraiwa S, Ichiki A, Kojima M, Ando K, Yokose T, Sakai R, Hoshikawa M, Tomita N, Miura I, Takata K, Yoshino T, Takizawa J, Bea S, Campo E, Nakamura N: Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Mod Pathol, 31(2): 313-326, 2018.
  22. Motohashi K, Fujisawa S, Doki N, Kobayashi T, Mori T, Usuki K, Tanaka M, Fujiwara S, Kako S, Aoyama Y, Onoda M, Yano S, Gotoh M, Kanamori H, Takahashi S, Okamoto S: Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia. Leuk Lymphoma, 59(6): 1332-1337, 2018.
  23. Nakajima Y, Yoshida C, Iriyama N, Fujisawa S, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H, Inokuchi K: Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study. Leuk Res, 66: 66-72, 2018.
  24. Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto KJ, Fujita H, Fujioka I, Kimura Y, Aisa Y, Iwanaga E, Asou N, Kizaki M, Hatta Y,Komatsu N, Kawaguchi T. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Med Onco, 35(7): 99, 2018.
  25. Ogata M, Takano K, Moriuchi Y, Kondo T, Ueki T, Nakano N, Mori T, Uoshima N, Nagafuji K, Yamasaki S, Shibasaki Y, Sakai R, Kato K, Choi I, Jo Y, Eto T, Kako S, Oshima K, Fukuda T: Effects of Prophylactic Foscarnet on Human Herpesvirus-6 Reactivation and Encephalitis in Cord Blood Transplant Recipients: A Prospective Multicenter Trial with an Historical Control Group. Biol Blood Marrow Transplant, 24(6): 1264-1273, 2018.
  26. Ogawa H, Ikegame K, Daimon T, Uchida N, Fukuda T, Kakihana K, Eto T, Ozawa Y, Kanamori H, Hidaka M, Iwato K, Ichinohe T, Takanashi M, Atsuta Y, Kanda Y: Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR. Bone Marrow Transplant, 53(4): 478-482, 2018.
  27. Saito H, Ito M, Kato S, Kodera Y, Okamoto S, Taniguchi S, Takanashi M, Kanamori H, Masaoka T, Takaku F on behalf of JMDP; The Japan Marrow Donor Program: 25 years of experience in achieving 20,000 bone marrow transplantations: organization structure, activity, and financial basis. Bone Marrow Transplant, 53(5): 609-616, 2018.
  28. Sakura T, Hayakawa F, Sugiura I, Murayama T, Imai K, Usui N, Fujisawa S, Yamauchi T, Yujiri T, Kakihana K, Ito Y, Kanamori H, Ueda Y, Miyata Y, Kurokawa M, Asou N, Ohnishi K, Ohtake S, Kobayashi Y, Matsuo K, Kiyoi H, Miyazaki Y, Naoe T: High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG. Leukemia, 32: 626-632, 2018.
  29. Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score. Leuk Lymphoma. 59(5): 1105-1112, 2018.
  30. Tachibana T, Kanda J, Machida S, Saito T, Tanaka M, Najima Y, Koyama S, Miyazaki T, Yamamoto E, Takeuchi M, Morita S, Kanda Y, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT): Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302). Int J Hematol, 107(5): 578-585, 2018.
  31. Tachibana T, Ando T, Tanaka M, Ito S, Miyazaki T, Ishii Y, Ogusa E, Koharazawa H, Takahashi H, Motohashi K, Aoki J, Nakajima Y, Matsumoto K, Hagihara M, Hashimoto C, Taguchi J, Fujimaki K, Fujita H, Fujisawa S, Kanamori H, Nakajima H: Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study. Clin Lymphoma Myeloma Leuk, 18(6): 415-421, 2018.
  32. Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, Takaku T, Iriyama N, Sato E, Fujita H, Hatta Y, Komatsu N, Asou N, Kizaki M, Kawaguchi T: Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol, 35(3): 38, 2018.
  33. Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Takahashi H, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Nakajima H, Miura I, Takeuchi K: The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis. Leuk Lymphoma, 59(1): 97-104, 2018.
  34. Yamamoto M, Ushio R, Watanabe H, Tachibana T, Tanaka M, Yokose T, Tsukiji J, Nakajima H, Kaneko T. Detection of Mycobacterium tuberculosis-derived DNA in circulating cell-free DNA from a patient with disseminated infection using digital PCR. Int J Infect Dis 66: 80-82, 2018.
  35. Yanada M, Mori J, Aoki J, Harada K, Mizuno S, Uchida N, Kurosawa S, Toya T, Kanamori H, Ozawa Y, Ogawa H, Henzan H, Iwato K, Sakura T, Ota S, Fukuda T, Ichinohe T, Atsuta Y, Yano S: Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. Leuk Lymphoma, 59: 601-609, 2018.
  36. 平川経晃, 黒澤彩子, 田島絹子, 山崎裕介, 池田奈未, 小島裕人, 田中秀則, 金森平和, 宮村耕一, 小寺良尚, 福田隆浩, 公益財団法人日本骨髄バンク. 骨髄バンクコーディネートの現状.臨床血液 59(2): 153-160, 2018.
  37. 石渡麻衣, 服部友歌子, 藤巻克通, 中堤啓太, 板橋健太郎, 田尻亮輔, 渡邉眞一郎, 中島秀明: 脾破裂を合併し脾動脈塞栓術と脾臓摘出術を行った有毛細胞白血病. 神奈川血液研究会誌 38:38-41, 2018.
  38. 菊池尚樹,中嶋ゆき,佐久間敬之,根来暁子,高橋寛行,宮崎拓也,萩原真紀,松本憲二,山崎悦子,中島秀明: T315I変異陰性フィラデルフィア染色体陽性急性リンパ性白血病の移植後再発にポナチニブが有効であった一例. 神奈川血液研究会誌, 38: 68-70, 2018.
  39. 成井崇朗,石井好美,安藤太基,鈴木泰生,寺中 寛,大草恵理子,青木 淳,宮下和甫,藤澤 信,中島秀明: 同種移植を行い,完全寛解に到達したアグレッシブNK細胞白血病. 神奈川血液研究会誌, 38: 17-19, 2018.
  40. 野本芽衣,髙橋寛行,佐久間敬之,根来暁子,中嶋ゆき,宮崎拓也,萩原真紀,松本憲二,山崎悦子,中島秀明: 当院で診断された血管内大細胞型B細胞リンパ腫の後方視的検討. 神奈川血液研究会誌, 38: 34-37, 2018.
  41. 貫井 淳,岸本久美子,徳永真由美,石橋大輔,長西裕樹,藤田浩之,中島秀明:rFVIIaで有効な止血が得られず、APCCへの切り換えと第XIII因子製剤の追加投与が奏功した後天性血友病A. 神奈川血液研究会誌, 38: 49-52, 2018.
  42. 坂田雄祐,服部友歌子,藤巻克通,渡邉眞一郎,中島秀明. アザシチジン療法により長期間造血回復を維持している骨髄異形成症候群の1例. 神奈川血液研究会誌 38:6-8, 2018.
  43. 佐久間敬之,髙橋寛行,根来暁子,中嶋ゆき,宮崎拓也,萩原真紀,松本憲二,上條亜紀,山崎悦子,中島秀明: 当院でG-CSF単独の前処置で末梢血幹細胞採取を施行した多発性骨髄腫患者27名の後方視的検討. 神奈川血液研究会誌, 38: 23-25, 2018.
  44. 佐久間敬之, 髙橋寛行,根来暁子,中嶋ゆき,江中牧子, 宮崎拓也, 萩原真紀,松本憲二,山崎悦子,中島秀明: DeVIC療法が奏功したBlastic plasmacytoid dentritic cell neoplasm. 神奈川血液研究会誌, 38: 76-81, 2018.
  45. 田中正嗣,青木 淳,石山泰史,小山 哲,立花崇孝,金森平和,中島秀明: 広範囲で高力価なHLA抗体を有する状態で臍帯血移植を施行した急性骨髄性白血病. 神奈川血液研究会誌, 38: 108-110, 2018.
  46. 勅使川原晴佳,佐久間敬之,松村彩子、根来暁子,高橋寛行、中嶋ゆき,宮崎拓也,萩原真紀,松本憲二,山崎悦子,山城安啓、中島秀明: Gγ-globin chain variantによる異常ヘモグロビンの1例. 神奈川血液研究会誌, 38: 90-93, 2018.
  47. 若月智詞,青木 淳,安藤太基,鈴木泰生,寺中 寛,大草恵理子,石井好美,宮下和甫,藤澤 信,中島秀明: BCR-ABLにp.C475fs*11変異が出現したCMLの一例. 神奈川血液研究会誌, 38: 71, 2018.
  48. 若松真央,石橋大輔,徳永真由美,岸本久美子,藤田浩之,中島秀明: MDSに対してエリスロポエチン製剤を投与中にPRCAとなりシクロスポリンが著効した一例. 神奈川血液研究会誌, 38: 105-107, 2018.

総説

  1. 藤田浩之:R-eraにおける多発性骨髄腫治療中の感染症マネージメント.神奈川血液研究会誌,38, 115-117, 2018.

著書

  1. 立花 崇孝: 非寛解期急性白血病に対する同種造血幹細胞移植 EBM血液疾患の治療2019-2020. 中外医学社, 544-548, 2018.
  2. 藤田浩之、ほか(分担執筆):造血器腫瘍診療ガイドライン 2018年版。日本血液学会編.金原出版,2018.

検索 ページトップへ